January 1997

Kaposi Sarcoma Unrelated to Human Immunodeficiency Virus Infection: Long-term Results of Radiotherapy

Author Affiliations

Servicio Oncología Radioterápica Clínica Puerta de Hierro San Mártin de Porres, 4 28035 Madrid, Spain


Arch Dermatol. 1997;133(1):107-108. doi:10.1001/archderm.1997.03890370119025

With great interest we read the article by Costa da Cunha et al1 on the treatment of Kaposi sarcoma (KS) unrelated to human immunodeficiency virus (HIV) infection in a recent issue of the Archives. Sixteen patients with KS in clinical stages I to IV were enrolled in a well-designed phase 2 trial testing the efficacy and safety of low-dose recombinant interferon alfa-2b administered for at least 6 months. The authors report encouraging patient response rates with this treatment approach. During a long-term follow-up, 10 patients had either complete or major responses, which were observed mostly in the initial stages (stages I and II) of KS.1

Based on these results, the authors conclude that low-dose interferon therapy is beneficial in patients with classic and endemic KS for both cutaneous and visceral lesions, and they propose a 6-month trial of interferon therapy. However, the authors fail to discuss how these

First Page Preview View Large
First page PDF preview
First page PDF preview